^
    2d
    CSG-301-101: SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Dec 2024 --> Jun 2026
    Trial completion date
    |
    CD38 (CD38 Molecule)
    |
    SG301 IV
    3d
    Isa_1q21+: Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+ (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New trial
    |
    carfilzomib • Sarclisa (isatuximab-irfc)
    3d
    IFm2022-01: Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=103, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    3d
    Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma. (PubMed, Blood)
    The combination of isatuximab and cemiplimab demonstrated sustained antitumor activity and a manageable safety profile in R/R ENKTL. This phase II trial is registered at www.clinicaltrials.gov as #NCT04763616.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Libtayo (cemiplimab-rwlc) • Sarclisa (isatuximab-irfc)
    4d
    Daratumumab in STK11 Mutated NSCLC (clinicaltrials.gov)
    P2, N=14, Recruiting, NYU Langone Health | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    4d
    POLLUX: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=569, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    6d
    RADIA: Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis (clinicaltrials.gov)
    P3, N=200, Active, not recruiting, The First People's Hospital of Changzhou
    New P3 trial
    |
    Darzalex (daratumumab) • Arzerra (ofatumumab)
    8d
    Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review. (PubMed, Cancer Med)
    Based on the results of this systematic review, BCMA-directed therapies such as CAR-T cell therapy and bispecific antibodies demonstrate promising efficacy among patients with anti-CD38 refractory disease. However, additional evidence from randomized clinical trials is necessary to establish best practice guidelines.
    Clinical • Review • Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • Elrexfio (elranatamab-bcmm) • Tecvayli (teclistamab-cqyv)
    8d
    SubQSA: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=64, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carfilzomib • dexamethasone • isatuximab subcutaneous (SAR650984 SC)
    8d
    Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Patients with Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=514, Active, not recruiting, University of Heidelberg Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • isatuximab subcutaneous (SAR650984 SC)
    9d
    GRAAL-2024: A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2/3, N=1200, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2/3 trial
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Sarclisa (isatuximab-irfc)
    12d
    Bibliometric and Bioinformatics Analysis of Renal Impairment in Multiple Myeloma: Trends and Research Hotspots, and Associated Genetic Pathways (2000-2023). (PubMed, J Multidiscip Healthc)
    Keywords such as "daratumumab", "carfilzomib", "diagnostic criteria" and "kidney biopsy" included recent research hotspots. Clinical physicians need to consider how to allocate medical resources reasonably, ensure that patients can receive necessary diagnosis and treatment, and explore cost-effective treatment options. The management of these patients requires interdisciplinary medical services, which should integrate basic and clinical research, especially the development of new treatment plans, to improve patients' quality of life and guide future treatment choices.
    Journal
    |
    TP53 (Tumor protein P53) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Darzalex (daratumumab) • carfilzomib
    15d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2026 --> Jan 2029
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    17d
    SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2029 --> Apr 2030 | Trial primary completion date: Nov 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • SX-682
    17d
    A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=96, Suspended, Hackensack Meridian Health | Trial completion date: Jan 2025 --> Jan 2026 | Recruiting --> Suspended | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Neofordex (dexamethasone acetate high-dose)
    17d
    NCI-2018-01432: Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Darzalex (daratumumab)
    19d
    2022-CM313-ITP: A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia (clinicaltrials.gov)
    P2, N=22, Completed, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Completed
    Trial completion
    20d
    A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P2, N=20, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Phase classification: P1 --> P2 | Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jan 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Phase classification • Trial completion date • Trial primary completion date
    |
    Darzalex (daratumumab)
    23d
    Anti-CD38 Antibody Treating Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=30, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Darzalex (daratumumab)
    26d
    Study of CM313 in Subject With IgA Nephropathy (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Keymed Biosciences Co.Ltd
    New P2 trial
    26d
    A Study of Felzartamab in Participants With Lupus Nephritis (clinicaltrials.gov)
    P1/2, N=20, Recruiting, HI-Bio, A Biogen Company | Phase classification: P1 --> P1/2
    Phase classification
    |
    felzartamab (MOR202)
    28d
    Impact of Quadruplet Induction Therapy on Stem Cell Mobilization Yields in Newly Diagnosed Multiple Myeloma. (PubMed, Transfus Clin Biol)
    Our results demonstrated that there were no statistically significant differences in achieving the patient-specific minimally required CD34+ cell yield after the first mobilization attempt between patients in the daratumumab-containing arm and those in the non-daratumumab-containing arm (P = 0.28).However, patients who received the quadruplet induction regimen with daratumumab experienced a statistically significant longer duration of apheresis collection (median of 2 days in the daratumumab-containing arm vs. 1 day in the non-daratumumab-containing arm, P = 0.011) than those who received traditional three-drug induction.Our findings reinforce the importance of incorporating both granulocyte-colony stimulating factors and plerixafor upfront into mobilization practices. Furthermore, the findings of this study may have implications for the judicious use of apheresis machines and further inform the optimal delivery of daratumumab-containing induction therapies for newly diagnosed multiple myeloma.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Darzalex (daratumumab) • plerixafor
    1m
    QL2109-101: A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults (clinicaltrials.gov)
    P1, N=228, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group. (PubMed, Clin Lymphoma Myeloma Leuk)
    In real-world, EPD is observed in more than one-fifth of patients, and it remains an unmet clinical need. Daratumumab-based therapies and ASCT significantly reduce the probability of EPD, while R2-ISS could serve as a useful prognostic tool for recognizing this population and guide therapeutic decisions.
    Journal • Real-world evidence
    |
    B2M (Beta-2-microglobulin)
    |
    lenalidomide • Darzalex (daratumumab)
    1m
    IMPEDE: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=53, Recruiting, Medical College of Wisconsin | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)
    1m
    A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Takeda | Trial completion date: Feb 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • pomalidomide • mezagitamab (TAK-079)
    1m
    Biomarkers of AKI in Patients Receiving Daratumumab (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Brigham and Women's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3)
    |
    Darzalex (daratumumab)
    1m
    IKEMA: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P3, N=302, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion
    |
    carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    1m
    Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Emory University | Trial completion date: Nov 2024 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Sarclisa (isatuximab-irfc)
    1m
    TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=290, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2025 --> Apr 2027
    Trial completion date
    |
    pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=7, Completed, Janssen Pharmaceutical K.K. | Phase classification: P1b --> P1
    Phase classification
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone
    1m
    Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=17, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2025 | Trial primary completion date: Jun 2026 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Darzalex (daratumumab)
    2ms
    Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency (clinicaltrials.gov)
    P2, N=41, Recruiting, Medical College of Wisconsin | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Sarclisa (isatuximab-irfc)
    2ms
    Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness (clinicaltrials.gov)
    P1/2, N=125, Not yet recruiting, Keymed Biosciences Co.Ltd
    New P1/2 trial
    2ms
    Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Keymed Biosciences Co.Ltd
    New P2 trial
    2ms
    Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia (clinicaltrials.gov)
    P1/2, N=125, Not yet recruiting, Keymed Biosciences Co.Ltd
    New P1/2 trial
    2ms
    A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=150, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Nov 2024 --> Aug 2025
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    2ms
    GMMG-HD7: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Dec 2025 --> Mar 2027
    Trial completion date
    |
    lenalidomide • bortezomib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    2ms
    A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lynozyfic (linvoseltamab)
    2ms
    International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • Libtayo (cemiplimab-rwlc) • carfilzomib • dexamethasone • pomalidomide • isatuximab subcutaneous (SAR650984 SC)
    2ms
    Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial. (PubMed, Blood)
    IsaKRD induction yielded deep responses and high MRD-negativity rates while ensuring successful stem cell collection, with no new safety signals. Continued follow-up of this ongoing study is required to confirm these findings.
    Journal
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc)
    2ms
    Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients (clinicaltrials.gov)
    P1, N=7, Completed, Biohaven Pharmaceuticals, Inc. | Recruiting --> Completed | N=25 --> 7
    Trial completion • Enrollment change
    |
    CD34 (CD34 molecule)
    |
    BHV-1100